Page 6 - ஆன்டிபாடி காக்டெய்ல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஆன்டிபாடி காக்டெய்ல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஆன்டிபாடி காக்டெய்ல் Today - Breaking & Trending Today

Roche's COVID-19 antibody cocktail launched in India : Bulletin: Business Today

Loading the player.
COVID vaccination key to curbing pandemic but govt doesn t seem to care: Rahul Gandhi
Asserting that the number of daily inoculations in the country has come down, Congress leader Rahul Gandhi on Monday said vaccination is the key to controlling the pandemic but the government does not seem to care. He shared a graph showing the decline in the number of vaccine doses administered during April and May (till 20th) and pointed out that the average number of vaccination per day has fallen below the daily production.
Kia Motors rebrands itself as Kia India
South Korean automaker Kia on Monday said it has officially changed its name in the country to Kia India from Kia Motors earlier. The change of name is part of the company s new brand identity which symbolises it becoming an enterprise that invests in and produces more than just vehicles to offer a long range of sustainable mobility solutions, it said. ....

United States , South Korea , South Korean , Elon Musk , Michael Saylor , Rahul Gandhi , Kia Motors , Central Drugs Standards Control Organisation , Kia India , Roche India , Emergency Use Authorisation , Bitcoin Mining , North America , Covid Vaccination , Coronavirus Pandemic , Rahul Gandhi On Vaccination , Kia Cars , Covid Antibody , Antibody Cocktail , Bitcoin Price , ஒன்றுபட்டது மாநிலங்களில் , தெற்கு கொரியா , தெற்கு கொரியன் , மைக்கேல் சாய்லோர் , ராகுல் காந்தி , கைய மோட்டார்கள் ,

Coronavirus Latest News Live Updates: Pfizer, Moderna refused to sell COVID-19 vaccines directly to Delhi govt, says AAP

Coronavirus Latest News Live Updates: RDIF, Panacea Biotec launch production of Sputnik V vaccine in India
Firstpost
35 minutes ago
FP Staff
© Provided by Firstpost
Coronavirus Latest News Live Updates: RDIF, Panacea Biotec launch production of Sputnik V vaccine in India
15:43 (IST)
RDIF and Panacea Biotec launch production of Sputnik V in India, say reports
Russia’s sovereign wealth fund RDIF says Panacea Biotec has begun production of Sputnik vaccine in India, reports
India Today, Panacea Biotec will produce 100 million doses of SputnikV per year. The first batch of Sputnik V produced at Panacea Biotec’s facilities will be shipped to the Gamaleya Research Institute of Epidemiology and Microbiology in Russia for quality control and full scale production is slated to start in the summer, reports the ....

Jammu And Kashmir , Uttar Pradesh , United Kingdom , Madhya Pradesh , Andaman And Nicobar Islands , India General , Tamil Nadu , Union Territory Of Puducherry , Ramesh Pokhriyal Nishank Drrpnishank , Smriti Irani , Barabanki Sisaurha , Amarinder Singh , Gautam Gambhir , Cn Ashwath Narayan , Manish Sisodia , Rajesh Rajora , Harsh Vardhan , Matt Hancock , Yoshihide Suga , Prakash Javadekar , Prasenjit Das , Rajiv Kumar Shukla , Ashwath Narayan , Arvind Kejriwal , Vikas Garg , Rajnath Singh ,

Coronavirus Latest News Live Updates: Supreme Court seeks Centre's reply on compensation to COVID-19 victims' kin

Coronavirus Latest News Live Updates: Over one crore Indians in 18-44 age group vaccinated so far, says health ministry
Firstpost
37 minutes ago
FP Staff
© Provided by Firstpost
Coronavirus Latest News Live Updates: Over one crore Indians in 18-44 age group vaccinated so far, says health ministry
15:29 (IST)
Coronavirus Latest Updates
Nothing wrong in Delhi govt order putting all doctors in one category for treating COVID patients,says HC
The Delhi High Court Monday said there was nothing wrong in the decision of the Delhi Government directing all doctors and medical staff to function in a single category, irrespective of the differences in their seniority and specialisation, in treatment of COVID patients, saying there should not be any ego issue . Justice Rekha Palli said that prima facie there was nothing wrong with the 16 May notification which appeared to be dealing only with COVID management duties of doctors a ....

Jammu And Kashmir , Uttar Pradesh , United Kingdom , Madhya Pradesh , Andaman And Nicobar Islands , Tamil Nadu , Union Territory Of Puducherry , Ramesh Pokhriyal Nishank Drrpnishank , Smriti Irani , Barabanki Sisaurha , Amarinder Singh , Gautam Gambhir , Cn Ashwath Narayan , Rajesh Rajora , Harsh Vardhan , Matt Hancock , Yoshihide Suga , Prakash Javadekar , Prasenjit Das , Rajiv Kumar Shukla , Ashwath Narayan , Arvind Kejriwal , Vikas Garg , Ramesh Pokhriyal , Rajnath Singh , Ashok Bhushan ,

Roche's Covid antibody cocktail launched at Rs 59,750/dose for treatment of mild to moderate patients

URL copied
Roche s Covid antibody cocktail launched in India for treatment of mild to moderate cases
Drug majors Roche India and Cipla on Monday announced launch of Roche s Antibody Cocktail in India priced at Rs 59,750 per dose for the treatment of mild to moderate COVID-19 in patients who are at high risk.
The first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 2,00,000 patients as each of the 1,00,000 packs that will be available in India offers treatment for two patients, Cipla and Roche said in a joint statement. ....

V Simpson Emmanuel , Umang Vohra , Roche Covid , Central Drugs Standards Control Organisation , Image Source , Roche India , Antibody Cocktail , Managing Director , Roche Pharma , Oche Covid Drug , Roche Antibody Cocktail , Covid Antibody Cocktail , Ntibody Cocktail In India , Ovid Antibody Cocktail Price , Oche Antibody Cocktail Price , வ் சிம்ப்சன் இம்மானுவேல் , உமங் வோஹ்ரா , மைய மருந்துகள் தரநிலைகள் கட்டுப்பாடு ஆர்கநைஸேஶந் , படம் மூல , ரோச் இந்தியா , ஆன்டிபாடி காக்டெய்ல் , நிர்வகித்தல் இயக்குனர் , ரோச் பார்மா ,

Cipla to distribute Antibody Cocktail (Casirivimab and Imdevimab) in India

Used in treatment of mild to moderate Covid-19 in adults and pediatric patients (12 years and older)Roche India and Cipla today announced that the first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June.
In total they can potentially benefit 200,000 patients as each of the 100,000 packs that will be available in India offers treatment for two patients. Cipla will distribute the prodmidluct by leveraging its strong distribution strengths across the country. The drug will be available through leading hospitals and COVID treatment centers.
The Central Drugs Standards Control Organisation (CDSCO) had recently provided an Emergency Use Authorisation (EUA) for the antibody ....

Central Drugs Standards Control Organisation , Roche India , Antibody Cocktail , Emergency Use Authorisation , Capital Market , Covid 19 , Occupational Safety And Health , Public Health , Antiviral Drugs , Covid 19 Drug Development , Treatment And Management Of Covid 19 , Sofosbuvir Velpatasvir , Harmaceuticals Nec , Central Drugs Standards Control , மைய மருந்துகள் தரநிலைகள் கட்டுப்பாடு ஆர்கநைஸேஶந் , ரோச் இந்தியா , ஆன்டிபாடி காக்டெய்ல் , மூலதனம் சந்தை ,